Defence Science and Technology Laboratory (DSTL) spinout Ploughshare Innovations has awarded £200,000 to Presymptom Health for the development of a test to predict whether Covid-19 patients will develop sepsis before symptoms appear.

The sepsis research is based on ten years of work done at DSTL. The research suggests that the test will be able to determine whether a patient will develop sepsis up to three days before becoming symptomatic.

Six months will now be spent developing the prototype diagnostic test, trialling the device on Covid-19 patients and testing samples from the DSTL biobank.